icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
UVu9gPG8HMyYCWqc